Nonclinical study and applicability of the absorbed dose conversion method with a single biodistribution measurement for targeted alpha-nuclide therapy.
Biodistribution
Dose conversion
Pharmacokinetics
RAP
Targeted alpha-nuclide therapy
Journal
EJNMMI physics
ISSN: 2197-7364
Titre abrégé: EJNMMI Phys
Pays: Germany
ID NLM: 101658952
Informations de publication
Date de publication:
11 Dec 2021
11 Dec 2021
Historique:
received:
31
05
2021
accepted:
19
11
2021
entrez:
13
12
2021
pubmed:
14
12
2021
medline:
14
12
2021
Statut:
epublish
Résumé
We recently reported a new absorbed dose conversion method, RAP (RAtio of Pharmacokinetics), for We derived a new formalism of the RAP dose conversion method at time t. In addition, we acquired a formula to determine the optimal timing of a single measurement of the percent injected dose/g, assuming the one-compartment model for biological clearance. We investigated the new formalism's performance using a representative RAP coefficient with radioactive decay weighting. Dose conversions by representative RAP coefficients predicted the true [ The RAP dose conversion method renovated by the new formalism was able to estimate the [
Sections du résumé
BACKGROUND
BACKGROUND
We recently reported a new absorbed dose conversion method, RAP (RAtio of Pharmacokinetics), for
METHODS
METHODS
We derived a new formalism of the RAP dose conversion method at time t. In addition, we acquired a formula to determine the optimal timing of a single measurement of the percent injected dose/g, assuming the one-compartment model for biological clearance.
RESULTS
RESULTS
We investigated the new formalism's performance using a representative RAP coefficient with radioactive decay weighting. Dose conversions by representative RAP coefficients predicted the true [
CONCLUSIONS
CONCLUSIONS
The RAP dose conversion method renovated by the new formalism was able to estimate the [
Identifiants
pubmed: 34897556
doi: 10.1186/s40658-021-00425-z
pii: 10.1186/s40658-021-00425-z
pmc: PMC8665908
doi:
Types de publication
Journal Article
Langues
eng
Pagination
80Subventions
Organisme : KAKENHI
ID : JP19H04296
Informations de copyright
© 2021. The Author(s).
Références
Med Phys. 2018 May;45(5):2318-2324
pubmed: 29577338
J Nucl Med. 2009 Jul;50(7):1153-60
pubmed: 19525452
EJNMMI Res. 2017 Dec;7(1):9
pubmed: 28102507
J Nucl Med. 2005 Jun;46(6):1023-7
pubmed: 15937315
EJNMMI Phys. 2021 Jan 12;8(1):4
pubmed: 33432383
Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):999-1010
pubmed: 29350258
J Nucl Med. 2010 Sep;51(9):1472-9
pubmed: 20720048
EJNMMI Phys. 2020 Sep 22;7(1):58
pubmed: 32960387
Nucl Med Biol. 1996 Aug;23(6):851-6
pubmed: 8940730
Cancer Biother Radiopharm. 2013 Nov;28(9):657-64
pubmed: 23789969
N Engl J Med. 1981 Jul 2;305(1):12-7
pubmed: 7231514
Ann Nucl Med. 2021 Jan;35(1):121-131
pubmed: 33222123
J Nucl Med. 2008 Jan;49(1):30-8
pubmed: 18077533
Lancet. 2005 Aug 20-26;366(9486):665-75
pubmed: 16112304